melanoma
MELANOMA
Melanoma is a skin neoplasm that originates from malignant transformation of melanocytes.
It commonly occurs in the extremities of women and on trunk or head and neck in men.
Metastases are via lymphatic and hematogenous routes.

Melanoma Drug Information

Drug Information

Indication: Tab: Multiple myeloma, advanced ovarian adenocarcinoma, breast carcinoma, polycythaemia rubra vera. Inj: Local...

Indication: Monotherapy or in combination w/ other chemotherapeutic agents for metastatic non-seminomatous germ cell carci...

Indication: Monotherapy or combination therapy for palliative treatment of metastatic non-seminomatous germ cell carcinoma...

Indication: Metastatic malignant melanoma & various sarcomas.

Indication: Acute leukemia. In combination w/ other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphom...

Indication: Breast, gastric, ovarian & small cell lung cancer; non-Hodgkin's lymphoma; advanced/metastatic soft tissue...

Indication: Breast, gastric, ovarian, small cell lung & superficial bladder (Tis, Ta) cancer, Non-Hodgkin's lymphoma, ...

Indication: Patients w/ a single demyelinating event w/ inflammatory process or multiple sclerosis of the relapsing/remitt...

Indication: Adult patients w/ BRAF V600 mutation +ve unresectable or metastatic melanoma.

1  /  2
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 6 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, Yesterday
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.